Colijn, Mark Ainsley http://orcid.org/0000-0002-8151-1173
Vrijsen, Stephanie http://orcid.org/0000-0002-2601-510X
Au, Ping Yee Billie http://orcid.org/0000-0002-9533-7217
Abou El Asrar, Rania http://orcid.org/0000-0001-9947-2697
Houdou, Marine http://orcid.org/0000-0002-9766-3163
Van den Haute, Chris http://orcid.org/0000-0002-6650-3845
Sarna, Justyna
Montgomery, Greg
Vangheluwe, Peter http://orcid.org/0000-0002-7822-2944
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (1S88419N, G094219N)
Aligning Science Across Parkinson’s (ASAP-000458, ASAP-000458, ASAP-000458, ASAP-000458, ASAP-000458)
Article History
Received: 26 April 2024
Accepted: 18 June 2024
First Online: 18 July 2024
Declarations
:
: The patient’s legal guardian has provided written informed consent for the publication of this report, and the patient himself has assented. KU Leuven Ethical Commission provided approval to work with human SHSY5Y cell lines.
: No AI or AI-assisted technologies were used in the preparation or writing of this manuscript.
: A longer version of this manuscript has previously been posted on the preprint server medRxiv (). It has otherwise not been published elsewhere and is not under consideration for publication elsewhere.
: MC has no conflicts of interest directly relevant to this paper. MC is a co-investigator for a RCT in generalized anxiety disorder sponsored by Sunovion and Sumitomo, and a study physician for a RCT in major depressive disorder partially funded by Otsuka (part of CAN-BIND). He also provides psychiatric consultation for the ATLAS study (Biogen). He has not received any money from these companies for this work. PV is involved in a drug discovery program for ATP13A2 agonists for Parkinson’s disease.